We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-12.58%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.2B
AUM Growth
+$58.8M
Cap. Flow
+$619M
Cap. Flow %
19.37%
Top 10 Hldgs %
58.78%
Holding
99
New
23
Increased
20
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$158M
2
ZLAB icon
Zai Lab
ZLAB
+$107M
3
ARVN icon
Arvinas
ARVN
+$93.6M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$70.9M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$59.4M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$81.7M
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$77.3M
3
RCUS icon
Arcus Biosciences
RCUS
+$75.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$63.6M
5
ITOS
iTeos Therapeutics
ITOS
+$44.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMTI
76
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$990K 0.03%
131,693
-268,307
-67% -$2.22M
TMPM
77
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$985K 0.03%
100,000
– –
CMAXW
78
DELISTED
CareMax, Inc. Warrant
CMAXW
$747K 0.02%
100,000
– –
RPTX
79
DELISTED
Repare Therapeutics
RPTX
$712K 0.02%
50,000
– –
CRBU icon
80
Caribou Biosciences
CRBU
$146M
$689K 0.02%
75,000
– –
EUCRW
81
CALL
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$656K 0.02%
+66,666
New +$27K
FLACW
82
DELISTED
Frazier Lifesciences Acquisition Corporation Warrant
FLACW
$655K 0.02%
66,665
– –
OMEG
83
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$491K 0.02%
50,000
– –
BOLT icon
84
Bolt Biotherapeutics
BOLT
$7.4M
$411K 0.01%
7,500
– –
TMPMW
85
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
$328K 0.01%
33,333
– –
RDUS
86
DELISTED
Radius Health, Inc.
RDUS
$309K 0.01%
+35,000
New +$265K
SRZNW icon
87
Surrozen Inc Warrant
SRZNW
$36.6K
$201K 0.01%
66,665
– –
ALNY icon
88
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-98,146
Closed -$16.6M
CRSP icon
89
CRISPR Therapeutics
CRSP
$4.69B
– –
-1,077,483
Closed -$81.7M
GLUE icon
90
Monte Rosa Therapeutics
GLUE
$1.82B
– –
-37,593
Closed -$768K
HALO icon
91
Halozyme
HALO
$9.88B
– –
-392,000
Closed -$15.8M
IMVT icon
92
Immunovant
IMVT
$7.93B
– –
-1,140,819
Closed -$9.72M
LEGN icon
93
Legend Biotech
LEGN
$3.65B
– –
-307,594
Closed -$14.3M
NGNE icon
94
Neurogene
NGNE
$672M
– –
-43,031
Closed -$4.15M
SAGE
95
DELISTED
Sage Therapeutics
SAGE
– –
-940,636
Closed -$40M
VTVT icon
96
vTv Therapeutics
VTVT
$124M
– –
-20,858
Closed -$830K
GRTS
97
CALL
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-307,000
Closed -$3.95M
GRTS
98
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-6,012,232
Closed -$77.3M
EUCRW
99
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
– –
-66,666
Closed -$27K
1 2 3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2022 Portfolio in Review

As of Q1 2022, EcoR1 Capital held 99 positions worth $3.2B, up 1.9% from $3.14B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

EcoR1 Capital deployed $619M of net new capital in Q1 2022, opening 23 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 2,069,634 shares worth $162M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $75.7M trimmed.

  • EcoR1 Capital's largest Q1 2022 buy was Sarepta Therapeutics: 2,069,634 shares worth $162M.
  • EcoR1 Capital added most to Arvinas in Q1 2022, an estimated $93.6M increase.
  • EcoR1 Capital's biggest Q1 2022 reduction was Arcus Biosciences, cutting an estimated $75.7M.
  • EcoR1 Capital fully exited CRISPR Therapeutics in Q1 2022, selling an estimated $81.7M.
  • EcoR1 Capital's ten largest holdings make up 59% of its $3.2B portfolio in Q1 2022.
  • EcoR1 Capital opened 23 new positions and closed 12 in Q1 2022.
  • EcoR1 Capital's portfolio value rose 1.9% quarter-over-quarter to $3.2B.

Based on EcoR1 Capital's 13F filing for Q1 2022, filed 16 May 2022.